Cogent Biosciences (COGT) Accumulated Expenses (2017 - 2026)

Cogent Biosciences' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 69.18% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 69.18% YoY), while the FY2025 annual figure was $52.9 million, up 25.56% from the prior year.
• Accumulated Expenses was $6.2 million for Q1 2026 at Cogent Biosciences, down from $52.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $52.9 million in Q4 2025 to a low of $2.2 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $17.4 million across 5 years, with a median of $12.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses soared 805.24% in 2024, then plunged 81.38% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $17.9 million in 2022, then soared by 46.09% to $26.1 million in 2023, then soared by 61.26% to $42.1 million in 2024, then climbed by 25.56% to $52.9 million in 2025, then sank by 88.27% to $6.2 million in 2026.
• The last three Accumulated Expenses figures came in at $6.2 million (Q1 2026), $52.9 million (Q4 2025), and $44.5 million (Q3 2025), per Business Quant data.